服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a receptor that is expressed on the surface of T cells and NK cells that binds to CD155 and CD112 on the surface of dendritic cells. Binding of TIGIT with CD155 or CD112 results in inhibition of T cell and NK cell activation. Antibodies and other agents that inhibit this signaling pathway have been shown to increase the immune response, especially in the case of certain cancers. 产品介绍 The Mouse TIGIT: Mouse CD155 (mTIGIT:mCD155) Homogeneous Assay Kit is designed to measure the inhibition of mTIGIT binding to mCD155. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing mTIGIT and an inhibitor of choice is incubated with the mCD155 for 60 minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against the viral infection. However recent reports showed that a mutant strain first identified in the UK (B1.1.7) exhibits higher transmissibility and infectivity. Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19. 产品介绍 The Spike RBD (SARS-CoV-2) UK variant (N501Y):ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the UK variant (N501Y) of the SARS-CoV-2 Spike RBD protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike RBD protein UK variant is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike RBD UK variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a luminometer or microplate reader capable of reading chemiluminescence.
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against the viral infection. However recent reports showed that a mutant strain first identified in the UK (B1.1.7) exhibits higher transmissibility and infectivity. Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19. 产品介绍 The Spike RBD (SARS-CoV-2) UK variant (N501Y):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the UK variant (N501Y) of the SARS-CoV-2 Spike RBD protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike RBD protein UK variant is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike RBD UK variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.
询价背景介绍 Nonalcoholic fatty liver disease (NAFLD) is a characterized by the aberrant accumulation of triglycerides in hepatocytes, even in the absence of significant alcohol consumption or viral infection. The FXR is a nuclear receptor that maintains bile acid homeostasis, and aberrant bile acid signaling via activation of FXR contributes liver disease. Several small molecule agonists have been developed and tested in clinical trials for NASH (Non-Alcoholic SteatoHepatitis), and the FXR pathway is also a molecular target in the search for novel cholesterol lowering agents. 产品介绍 The FXR (Farnesoid X Receptor) Agonist Assay Kit (TR-FRET) is designed to measure binding of the FXR and SRC-1 (Steroid Receptor Coactivator 1) for screening FXR agonists using TR-FRET technology. With this homogeneous kit, the FXR agonist assay can be performed by adding all materials, including the detection reagents, to the wells and incubating the plate for 2-hours at room temperature followed by reading the TR-FRET signal.
询价背景介绍 Janus kinases (JAKs) are a family of intracellular nonreceptor tyrosine kinases including JAK1, JAK2, JAK3 and Tyk2, that has been recognized as an important modulator in inflammatory processes. JAKs contain a catalytically inactive pseudokinase regulatory domain (JH2) as well as an active kinase domain (JH1). Selective inhibition of one specific JAK is a challenging task since the enzymes share high homology in the active site of JH1. Recent reports demonstrate that the pseudokinase domain (JH2) could provide an ideal allosteric site for selective inhibitor development. 产品介绍 The JAK2 JH2 Pseudokinase Domain Inhibitor Screening Assay Kit is designed for screening and profiling small molecules that displace the fluorescently labeled probe (JH2 probe 1) from the JH2 domain of JAK2. The assay is based on the competition of the test compound with the JH2 probe for binding to purified JAK2 JH2. Using this kit, only one simple step on a microplate is required for screening. The JH2 probe 1 is incubated with a sample containing JAK2 JH2 to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.
询价背景介绍 CD38, a differentiation antigen of B lymphocytes, is a type II integral membrane protein that functions as an ADP-ribosyl cyclase and nicotinamide adenine dinucleotide (NAD) glycohydrolase. The major enzymatic activity of CD38 is the hydrolysis of NAD. Through its production of cyclic ADP-ribose, CD38 modulates calcium-mediated signal transduction in various cells, including pancreatic ß cells. CD38 is a prognostic biomarker for acute B lymphoblastic leukemia. 产品介绍 The Dog CD38 Inhibitor Screening Assay Kit (Hydrolase Activity) is designed to measure the glycohydrolase activity of canine CD38 for screening and profiling applications.
询价背景介绍 Janus kinases (JAKs) are a family of intracellular nonreceptor tyrosine kinases including Jak1, Jak2, Jak3 and TYK2, that has been recognized as an important modulator in inflammatory processes. JAKs contain a catalytically inactive pseudokinase regulatory domain (JH2) as well as an active kinase domain (JH1). Selective inhibition of one specific Jak is a challenging task since the enzymes sharehigh homology in the active site of JH1. Recent reports demonstrate that the pseudokinase domain (JH2) could provide an ideal allosteric site for selective inhibitor development. 产品介绍 The TYK2 JH2 Pseudokinase Domain Inhibitor Screening Assay Kit is designed for screening and profiling small molecules that displace the fluorescently labeled probe (JH2 probe 1) from the JH2 domain of TYK2. The assay is based on the competition of the test compound with the JH2 probe for binding to purified TYK2 JH2. Using this kit, only one simple step on a microplate is required for screening. The JH2 probe 1 is incubated with a sample containing TYK2 JH2 to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.
询价产品介绍
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.
This sgRNA (single guide RNA) pool is designed for use with the CRISPR Synergistic Activation Mediator (SAM) system to induce transcriptional activation and expression of any gene of interest. CRISPRa (SAM) cells stably express a mutated dCas9 (Streptococcus pyogenes CRISPR associated protein 9), lacking any endonuclease activity, fused with VP64, a transcriptional activator, as well as transcription factors P65 (Transcription Factor p65, or Nuclear Factor NF-κB p65) and HSF1 (Heat Shock Factor 1) fused with an MS2 tag.
When these cells are transfected with an MS2-tagged sgRNA targeting the promoter region of PD-1 (Programmed Cell Death 1, PDCD1, CD279, GenBank Accession #NM_005018), dCas9-VP64 and MS2-P65-HSF1 are recruited to the site in the genomic DNA and begin transcription, inducing PD-1 expression. Each pool includes 5 individually validated sgRNA to ensure robust expression.
| Gene Target: | Primer ID: | sgRNA Sequence: |
| PD-1 | PD-1-1A | AGGGAGAGAGAGACAGAGAC |
| PD-1 | PD-1-2A | AGGGGGCGGGAGCAAGGGGC |
| PD-1 | PD-1-3A | GGGAGACAGAGGAGATGGGG |
| PD-1 | PD-1-4A | GACAGAGGCAGTGCTGGGGG |
| PD-1 | PD-1-5A | GGGTGAGGAGGGGGTAGGAC |
背景介绍 Transmembrane protease, serine 2 is an enzyme that belongs to the serine protease family. It has been implicated as a target in prostate cancer. TMPRSS2 facilitates SARS-CoV-2 particle entry into host cells via S protein priming, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 viral entry, making TMPRSS2 an important therapeutic target. 产品介绍 The key to the TMPRSS2 Fluorescent Assay Kit is the fluorogenic substrate. Using this kit, only one simple step on a microtiter plate is required for TMPRSS2 reactions. A sample containing TMPRSS2 is incubated in a reaction mixture with the fluorogenic substrate and fluorescence (λex=383nm, λem=455nm) is measured using a plate reader. Camostat is supplied as a protease inhibitor control.
询价
